Immune response in hormonally-induced prostatic hyperplasia in the dog

Mahapokai, W.; Ingh, T. S. G. A. M. van den; Mil, F. van; Garderen, E. van; Schalken, Jack A.; Mol, Jan A.; Sluijs, F.J. van

doi:10.1016/s0165-2427(01)00236-7

Cited by 19 publications

(8 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As in humans, most dogs develop a certain degree of BPH with increasing age [28]. In contrast to man however, where BPH develops in a nodular fashion in the transition zone of the prostate, the condition in dogs affects the gland diffusely [29]. In addition, no preferential site of initiation of prostate cancer in the canine prostate has been mentioned in the literature.…”

Section: Discussionmentioning

confidence: 99%

Comparative characterization of the canine normal prostate in intact and castrated animals

et al. 2008

View full text Add to dashboard Cite

Background Prostate diseases in the dog are generally regarded as representative for their human counterparts. We characterized the normal canine prostate in comparison to the normal human prostate. Methods Prostates of dogs were examined histomorphologically and by immunohistochemical detection of the markers CK14, HMWCK, CK5, CK18, CK7, UPIII, PSA, and PSMA. Results Histomorphologically, the canine prostate lacks the human zonal differentiation, has much more prominent acini, while comprising less stromal tissue. In general, the canine prostate epithelium displayed a highly differentiated character, with no cells expressing CK14, minimal amounts of cells expressing HMWCK/CK5 and the vast majority of cells expressing CK18 and PSA. After castration, the prostate epithelium regressed, and the remaining tubules were largely populated by cells showing a ductal phenotype (HMWCK+/CK5+/CK18+/CK7+). Conclusions The human and canine prostate are histologically differently organized. The general scheme of cellular differentiation of the prostate epithelium may however be applicable to both species. Prostate 68: 498–507, 2008. © 2008 Wiley‐Liss, Inc.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparative characterization of the canine normal prostate in intact and castrated animals

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Inflammation was frequently observed in hormonally induced hypertrophied prostates of dogs [32] and in a study of human BPH [33] . Mahapokai et al [32] concluded that the development of hyperplasia preceded inflammatory infiltration. An anti-inflammatory effect was indicated as one of the mechanisms of action of SPE.…”

Section: Anti-inflammatory Effectsmentioning

confidence: 98%

Pharmacological effects of saw palmetto extract in the lower urinary tract

et al. 2009

View full text Add to dashboard Cite

Saw palmetto extract (SPE), an extract from the ripe berries of the American dwarf palm, has been widely used as a therapeutic remedy for urinary dysfunction due to benign prostatic hyperplasia (BPH) in Europe. Numerous mechanisms of action have been proposed for SPE, including the inhibition of 5alpha-reductase. Today, alpha(1)-adrenoceptor antagonists and muscarinic cholinoceptor antagonists are commonly used in the treatment of men with voiding symptoms secondary to BPH. The improvement of voiding symptoms in patients taking SPE may arise from its binding to pharmacologically relevant receptors in the lower urinary tract, such as alpha(1)-adrenoceptors, muscarinic cholinoceptors, 1,4-dihyropyridine receptors and vanilloid receptors. Furthermore, oral administration of SPE has been shown to attenuate the up-regulation of alpha(1)-adrenoceptors in the rat prostate induced by testosterone. Thus, SPE at clinically relevant doses may exert a direct effect on the pharmacological receptors in the lower urinary tract, thereby improving urinary dysfunction in patients with BPH and an overactive bladder. SPE does not have interactions with co-administered drugs or serious adverse events in blood biochemical parameters, suggestive of its relative safety, even with long-term intake. Clinical trials (placebo-controlled and active-controlled trials) of SPE conducted in men with BPH were also reviewed. This review should contribute to the understanding of the pharmacological effects of SPE in the treatment of patients with BPH and associated lower urinary tract symptoms (LUTS).

show abstract

“…Although the use of autoantibody profiling in BPH has not been reported, observations have shown that the majority of BPH tissues demonstrate significantly increased T-lymphocyte infiltration. 9,10,11 In addition, Mahapokai et al 12 have reported that in a hormonallyinduced BPH canine model, hyperplasia was followed by cell-mediated and humoral immune responses. Finally, using expression microarrays and prostate tissues from symptomatic and asymptomatic BPH samples, Prakash et al 13 demonstrated that there is strong correlation between inflammation and symptomatic BPH.…”

Section: Reverse-capture Autoantibody Platform For Identification Of mentioning

confidence: 99%

A Comprehensive Approach Toward Novel Serum Biomarkers for Benign Prostatic Hyperplasia: The MPSA Consortium

et al. 2008

View full text Add to dashboard Cite

Purpose-Clinical benign prostatic hyperplasia (BPH) is primarily diagnosed based on a diverse array of progressive lower urinary tract symptoms (LUTS) and is likely distinct from histological BPH, which is detected by the presence of non-malignant proliferation of prostate cells but may or may not be associated with symptoms. Pharmacological management of LUTS has emerged as an effective initial treatment for clinical BPH due to the introduction of new drug therapies shown to be effective in recent large clinical trials. Despite advances in symptom management and research into BPH pathology, diagnostic strategies for prediction of BPH progression and response to drug modalities are lacking and questions remain as to the molecular differences underlying clinical (symptomatic) versus histological (non-symptomatic) BPH. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Results-To date the MPSA has identified a number of promising biomarkers and other molecular and cellular changes associated with BPH. NIH Public AccessConclusions-These findings and ongoing consortium discovery efforts have the potential to provide a greater understanding of the defects underlying disease pathology and may lead to the development of early and more effective pharmacological treatment strategies for BPH.

show abstract

Immune response in hormonally-induced prostatic hyperplasia in the dog

Cited by 19 publications

References 17 publications

Comparative characterization of the canine normal prostate in intact and castrated animals

Comparative characterization of the canine normal prostate in intact and castrated animals

Pharmacological effects of saw palmetto extract in the lower urinary tract

A Comprehensive Approach Toward Novel Serum Biomarkers for Benign Prostatic Hyperplasia: The MPSA Consortium

Contact Info

Product

Resources

About